Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Change in Account Payables: 2017-2024

Historic Change in Account Payables for BridgeBio Pharma (BBIO) over the last 8 years, with Dec 2024 value amounting to $1.5 million.

  • BridgeBio Pharma's Change in Account Payables fell 106.39% to -$7.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.3 million, marking a year-over-year decrease of 53.33%. This contributed to the annual value of $1.5 million for FY2024, which is 45.61% down from last year.
  • Per BridgeBio Pharma's latest filing, its Change in Account Payables stood at $1.5 million for FY2024, which was down 45.61% from $2.8 million recorded in FY2023.
  • In the past 5 years, BridgeBio Pharma's Change in Account Payables ranged from a high of $2.8 million in FY2021 and a low of -$735,000 during FY2020.
  • Its 3-year average for Change in Account Payables is $1.3 million, with a median of $1.5 million in 2024.
  • Per our database at Business Quant, BridgeBio Pharma's Change in Account Payables tumbled by 112.32% in 2022 and then skyrocketed by 896.56% in 2023.
  • Over the past 5 years, BridgeBio Pharma's Change in Account Payables (Yearly) stood at -$735,000 in 2020, then soared by 485.44% to $2.8 million in 2021, then tumbled by 112.32% to -$349,000 in 2022, then soared by 896.56% to $2.8 million in 2023, then plummeted by 45.61% to $1.5 million in 2024.